Publication

Article

Pharmacy Times
September 2012 Oncology
Volume 79
Issue 9

Genetic Aberrations in Oral Dysplasia Point to Cancer Progression

Chromosomal changes at the allele level were recently found to influence the progression of oral dysplasia into malignant lesions, according to a new prospective study of 296 patients with mild or moderate keratotic abnormalities.

To fully understand how oral precancers can become cancerous, scientists in this study used their prior research, which showed that loss of heterozygosity (LOH) on the short arms of chromosomes 3 and 9 was associated with oral cancer development. LOH occurs when a somatic cell heterozygous for a deleterious mutant allele and a normal allele goes through a deletion or other mutational event on the normal copy, rendering the gene inactive. This gene inactivation could stop the production of tumor suppressor genes.

Investigators grouped the patients into low-, intermediate-, and high-risk groups based on the chromosomal location of the LOH. Five-year progression rates were found to be 3.1% for the low-risk group, 16.3% for the intermediate-risk group, and 63.1% for the high-risk group. This means that 2 of 3 high-risk cases are progressing, according to the study authors.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com